 |
 |
 |
 |
About Zyprexa Zyprexa, made by Eli Lilly, is commonly prescribed for the treatment of schizophrenia. It is one of the most frequently prescribed drugs for this condition and the most frequently associated with serious side effects. According to an article in the Wall Street Journal, "of the millions of patients who took the drug over an eight-year period that ended in 2002, 288 are reported to have developed diabetes. Seventy-five of those people became severely ill, and 23 died. Some researchers see these statistics as significant because in some cases, life-threatening diabetes symptoms came on suddenly after patients began taking Zyprexa and eased after they went off the drug." In January 2004, Zyprexa was one of six antipsychotic drugs cited by four U.S. medical groups. They said Zyprexa carries the biggest risk for weight gain, diabetes and lipid disorders. The report was issued by the American Diabetes Association, the American Psychiatric Association, The American Association of Clinical Endocrinologists and the North American Association for the Study of Obesity. |
 |
 |
 |
 |
 |
 |
 |
Drug Category/Class Schizophrenia, Antipsychotics |
 |
Generic Name Olzanapine |
 |
Zyprexa Manufacturer Eli Lilly |
 |
Adverse Effects Diabetes, Hyperglycemia, severe weight gain, lipid disorders |
 |
Common Misspellings Ziprexa |
 |
 |
Zyprexa, an anti-psychotic drug manufactured and marketed by the Eli Lilly Company, is being sued by thousands of patients who claim that their use of the medication has adversely affected their health. Zyprexa has allegedly made them leading risks for heart attacks and other ailments. MORE
The Zyprexa Story
The controversy surrounding the Eli Lilly anti-psychotic drug Zyprexa would seem to have reached its culmination with the announcement of a $500 million settlement for 18,000 lawsuits on January 5, 2007. This is in addition to a $700 million settlement reached in 2005 for 8,000 lawsuits from patients who developed diabetes and other complications due to their use of Zyprexa since the drug’s introduction in 1996. MORE
